AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 91 min read$UTHR

ROTHBLATT MARTINE A sold $5.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $534.31 ($525.50–$541.23, $5.08M total) across 16 trades on 2026-10-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 9, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, prompting short‑term price weakness.

02

Market read

Insider sales of this size are noteworthy for investors tracking ownership changes; the filing may trigger modest sell pressure.

03

What to watch

Potential upcoming clinical data or regulatory events that could offset the sell‑off.

Relevance 5/10Novelty 6/10Timing: post‑market filing on 2026‑10‑09

Background

Form 4 filing discloses insider transactions required by the SEC, providing transparent ownership changes.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $5.1M of United Therapeutics shares via a 10b5-1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $5M sale by the chairperson is material for a mid‑cap biotech and often triggers short‑term selling pressure.

Market effects

Sector

May raise concerns for the biotech sector about insider sentiment.

Regional

Limited to U.S. markets where United Therapeutics trades.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

The sale could be a routine 10b5‑1 execution unrelated to company fundamentals.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other conditions.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min